Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aneurysmal subarachnoid hemorrhage~* World Federation of Neurological Surgeons (WFNS) grade 4-5 (see table below)~* Surgical intervention with clip or coil~* Placement of cerebrospinal fluid drain (lumbar or ventricular)~* Mechanically ventilated at start of infusion~Exclusion Criteria:~* Hemodynamic instability (SBP \< 100, HR \<60, or on continuous infusion of catecholamines) at screening~* Heart failure class III or IV (New York Heart Association)~* Renal failure (RIFLE classification - see table below)~* Liver failure (serum protein \< 3 g/dL and total bilirubin \> 5 mg/dL)~* Known or suspected brain death~* Pregnancy~* Unable to receive dexmedetomidine within 48 hours of injury and 4 hours of surgery~* Allergy to dexmedetomidine~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): None
- Dexmedetomidine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).